Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
BMC Cancer|May 25, 2018
Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumorsSini L Karjalainen, Hannu K Haapasalo, Ashok Aspatwar, et al.Oncogene|January 12, 2019
Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targetingHanna Karvonen, Robert Perttilä, Wilhelmiina Niininen, et al.International Journal of Molecular Sciences|July 19, 2017
Zebrafish as a Model Organism for the Development of Drugs for Skin CancerFatemeh Bootorabi, Hamed Manouchehri, Reza Changizi, et al.Journal of Enzyme Inhibition and Medicinal Chemistry|June 21, 2017
β-CA-specific inhibitor dithiocarbamate Fc14-584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosisAshok Aspatwar, Milka Hammarén, Sanni Koskinen, et al.Experimental Eye Research|October 17, 2017
Furin deficiency in myeloid cells leads to attenuated revascularization in a mouse-model of oxygen-induced retinopathyMaria Vähätupa, Zuzet Martinez Cordova, Harlan Barker, et al.Journal of Enzyme Inhibition and Medicinal Chemistry|November 6, 2019
Design, synthesis, <i>in vitro</i> inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole seriesAshok Aspatwar, Nanda Kumar Parvathaneni, Harlan Barker, et al.Physiological Reviews|February 15, 2022
Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiologyAshok Aspatwar, Martti E E Tolvanen, Harlan Barker, et al.Molecular Therapy. Oncology|December 5, 2024
Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responsesEmilia Piki, Alice Dini, Frida Rantanen, et al.Experimental Dermatology|November 30, 2018
R-Ras regulates vascular permeability, but not overall healing in skin woundsTuomo Ketomäki, Maria Vähätupa, Ulrike May, et al.Cell Death & Disease|February 26, 2026
ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancerJuuli Raivola, Frida Rantanen, Alice Dini, et al.Pageof 3